Pfizer to buy antibody developer

In a move to shore up its antibody pipeline, Pfizer announced that it intends to buy Bioren, a privately-held biotech based in San Carlos, California. The drug giant said the small company's antibody-development technologies will help it identify new antibodies and improve those it's already developing.

- read this AP story for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.